Skip to content

Source filing unavailable

Q3 2023 · —
Revenue—
Net Income-$6.34Mno prior Q3 2022 on fileN/M vs Q2 2023
EPS Diluted-$4.31no prior Q3 2022 on fileN/M vs Q2 2023
Operating Income-$6,475,673—
Operating Cash Flowderived-$5,638,251—

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

no prior Q3 2022 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Actuate Therapeutics, Inc. · CIK 1652935 · Engraved from SEC EDGAR